Results 191 to 200 of about 3,661 (213)

Management of symptomatic vulvovaginal atrophy

Menopause, 2013
To update and expand the previous position statement of The North American Menopause Society (NAMS) on the management of symptomatic vulvovaginal atrophy (VVA) in postmenopausal women.NAMS searched PubMed for medical literature on VVA published since their 2007 position statement on the role of local vaginal estrogen for treatment of vaginal atrophy in
openaire   +3 more sources

Prasterone: A Review in Vulvovaginal Atrophy

Drugs & Aging, 2019
Vulvovaginal atrophy (VVA) is a progressive condition commonly seen in postmenopausal women. The cessation of ovarian estrogen secretion and a fall in serum levels of dehydroepiandrosterone (DHEA), the remaining source of estrogens and androgens, are thought to promote the development of VVA in this population. Intravaginal prasterone (Intrarosa®) is a
openaire   +2 more sources

The European Vulvovaginal Epidemiological Survey (EVES): impact on sexual function of vulvovaginal atrophy of menopause

Menopause, 2020
Abstract Objective: To estimate the impact of vulvovaginal atrophy (VVA) on sexual function in a clinical population of postmenopausal women. Methods: Women 45 to 75 years old and more than 12 months after the last menstruation, who attended menopausal/gynecological ...
Particco M., Djumaeva S., Nappi R. E., Panay N., Palacios S.   +4 more
openaire   +3 more sources

Treatment of Dyspareunia Secondary to Vulvovaginal Atrophy

Nursing for Women's Health, 2014
Declining estrogen levels associated with menopause can result in vulvovaginal atrophy and some degree of dyspareunia for more than half of all women in menopause. In 2013, the U.S. Food and Drug Administration approved ospemifene, a nonhormonal oral medication for the treatment of dyspareunia in menopause.
openaire   +2 more sources

Advances in the treatment of vulvovaginal atrophy

Expert Review of Obstetrics & Gynecology, 2013
Vulvovaginal atrophy is a frequently neglected symptom of menopause. While an estimated 10–40% of women are affected by the progressive symptoms of vaginal dryness, irritation, itching, dysuria and dyspareunia, only a quarter of symptomatic women are believed to seek medical attention. Until recently, treatments for vulvovaginal atrophy were limited to
Jill M Krapf, Zoe R Belkin, Andrew T Goldstein   +2 more
openaire   +1 more source

Laser Treatment for Vulvovaginal Atrophy

2019
Laser therapy has a therapeutic role for different medical conditions and most recently has gained interest as a non-hormonal treatment for vulvovaginal atrophy or genitourinary syndrome of menopause (GSM). Both microablative fractional CO2 laser and the second-generation non-ablative vaginal Er:YAG laser (VEL) can alleviate the symptoms of dryness and
openaire   +1 more source

[Sulphurous vaginal douching and vulvovaginal atrophy].

La Clinica terapeutica, 2018
During climacteric the reduction or interruption of estrogenic stimulus determines a gradual atrophy of the tissues of the urogenital tract.Vulvovaginal atrophy can be cause of dryness, itch, burning, and dyspareunia. Vulvovaginal atrophy is associated also with depression.
M, Costantino, V, Conti, M B, Marongiu, G, Napolano, A, Filippelli   +4 more
openaire   +1 more source

Fractional CO2 Laser for Vulvovaginal Atrophy.

Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2018
To evaluate the short term efficacy and safety of Fractional CO2 laser for the treatment of vulvovaginal atrophy.From March 2015 to October 2015, 112 menopausal women were recruited. All women with VVA were treated by using Fractional CO2 laser; power 30 watts, 1-3 stacks with 360° vaginal probe for 3 consecutive times, 4 weeks apart.
Orawan, Lekskulchai, Karicha, Mairaing, Nipattha, Vinayanuvattikhun   +2 more
openaire   +1 more source

Current and Emerging Treatment Options for Vulvovaginal Atrophy

2014
Vulvovaginal atrophy in postmenopausal women is common and manifests in vaginal dryness, irritation, itching, dysuria, and dyspareunia. Treatment used to be limited to estrogen-containing regimens which pose safety concerns. Today, however, practitioners are becoming better equipped to offer a wider range of treatment options due to increased ...
Jill M. Krapf, Zoe Belkin, Frank Dreher, Andrew T. Goldstein   +3 more
openaire   +1 more source

Vulvovaginal atrophy: current and future therapies (CME).

The journal of sexual medicine, 2010
Vulvovaginal atrophy results from estrogen deficiency and affects a large number of postmenopausal women. Symptoms include vaginal dryness, itching, irritation, and dyspareunia.The purpose of this review is to evaluate the efficacy, safety and acceptability of current treatment methods for vulvovaginal atrophy, as well as highlight evolving new ...
Comfort, Ibe, James A, Simon
openaire   +1 more source